Dr. Sunil Agarwal brings over 25 years of experience in global drug development, translational medicine, and organizational leadership across biotechnology and large pharmaceutical companies.

Previously, he served as Executive Vice President, Head of Development, and Chief Medical Officer at Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines for patients. Prior to Sana, he was President of Research and Development at Juno Therapeutics, which was acquired by Celgene for $9 billion. Earlier in his career, he served as Executive Vice President and Chief Medical Officer at Ultragenyx Pharmaceutical. He spent more than a decade at Genentech as Senior Vice President and Global Head of Clinical Development for ophthalmology, metabolism, neurosciences, immunology, and infectious diseases. During his tenure, he led the approvals and line extensions of multiple important therapies, including RITUXAN, ACTEMRA, LUCENTIS, and XOLAIR. He has also served on the boards of directors of several companies, including MyoKardia (acquired for $13.1 billion), HiBio (acquired for $1.15 billion), and Astria Therapeutics (acquired for $920 million).

He completed his residency at Children’s National Medical Center in Washington, D.C. and practiced in the Pediatric Emergency Department and Level 1 Trauma Center. He holds a B.S. in Neurobiology from Cornell University and an M.D. from Tufts University School of Medicine.